1. Academic Validation
  2. Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201

Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201

  • Bioorg Med Chem. 2014 Jun 1;22(11):3021-9. doi: 10.1016/j.bmc.2014.03.036.
Nobuhiko Hayakawa 1 Masatsugu Noguchi 1 Sen Takeshita 1 Agung Eviryanti 1 Yukie Seki 1 Hikaru Nishio 1 Ryohei Yokoyama 1 Misato Noguchi 1 Manami Shuto 1 Yoichiro Shima 1 Kanna Kuribayashi 1 Shunsuke Kageyama 1 Hiroyuki Eda 1 Manabu Suzuki 1 Tomohisa Hatta 2 Shun-Ichiro Iemura 2 Tohru Natsume 2 Itsuya Tanabe 1 Ryusuke Nakagawa 1 Makoto Shiozaki 1 Kuniya Sakurai 1 Masataka Shoji 1 Ayatoshi Andou 3 Takashi Yamamoto 4
Affiliations

Affiliations

  • 1 Research Institute, Ajinomoto Pharmaceuticals Co. Ltd, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, Japan.
  • 2 Molecular Profiling Research Center for Drug Discovery (molprof), National Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan.
  • 3 Research Institute, Ajinomoto Pharmaceuticals Co. Ltd, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, Japan. Electronic address: ayatoshi_andou@ajinomoto.com.
  • 4 Research Institute, Ajinomoto Pharmaceuticals Co. Ltd, 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, Japan. Electronic address: takashia_yamamoto@ajinomoto.com.
Abstract

Interleukin-12 (IL-12) and IL-23 are proinflammatory cytokines and therapeutic targets for inflammatory and autoimmune diseases, including inflammatory bowel diseases, psoriasis, rheumatoid arthritis, and multiple sclerosis. We describe the discovery of APY0201, a unique small molecular IL-12/23 production inhibitor, from activated macrophages and monocytes, and demonstrate ameliorated inflammation in an experimental model of colitis. Through a chemical proteomics approach using a highly sensitive direct nanoflow LC-MS/MS system and bait compounds equipped with the FLAG epitope associated regulator of PIKfyve (ArPIKfyve) was detected. Further study identified its associated protein phosphoinositide kinase, FYVE finger-containing (PIKfyve), as the target protein of APY0201, which was characterized as a potent, highly selective, ATP-competitive PIKfyve Inhibitor that interrupts the conversion of phosphatidylinositol 3-phosphate (PtdIns3P) to PtdIns(3,5)P2. These results elucidate the function of PIKfyve kinase in the IL-12/23 production pathway and in IL-12/23-driven inflammatory disease pathologies to provide a compelling rationale for targeting PIKfyve kinase in inflammatory and autoimmune diseases.

Keywords

APY0201; IL-12/23; PIKfyve; Target identification.

Figures
Products